Effects of tolcapone, a catechol-O-methyltransferase inhibitor, on motor symptoms and pharmacokinetics of levodopa in patients with Parkinson's disease
- 1 February 1997
- journal article
- clinical trial
- Published by Springer Nature in Journal Of Neural Transmission-Parkinsons Disease and Dementia Section
- Vol. 104 (2-3) , 229-236
- https://doi.org/10.1007/bf01273183
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease.Journal of Neurology, Neurosurgery & Psychiatry, 1994
- 3‐O‐methyldopa administration does not alter fluorodopa transport into the brainAnnals of Neurology, 1992
- Rationale for Selective COMT Inhibitors as Adjuncts in the Drug Treatment of Parkinson's DiseaseBasic & Clinical Pharmacology & Toxicology, 1990
- Simple automated high-performance liquid chromatographic column-switching technique for the measurement of dopa and 3-O-methyldopa in plasmaJournal of Chromatography B: Biomedical Sciences and Applications, 1990
- Motor fluctuations in Parkinson's disease: Pathogenetic and therapeutic studiesAnnals of Neurology, 1987
- Clinical Pharmacokinetics of Anti-Parkinsonian DrugsClinical Pharmacokinetics, 1987
- Pharmacokinetics of LevodopaClinical Neuropharmacology, 1984
- 3‐O‐ methyldopa blocks dopa metabolism in rat corpus striatumAnnals of Neurology, 1982
- SUCCESS AND PROBLEMS OF LONG-TERM LEVODOPA THERAPY IN PARKINSON'S DISEASEThe Lancet, 1977
- 3-O-Methyldopa, a New Precursor of DopamineNature, 1971